Diphlorethohydroxycarmalol Attenuates Palmitate-Induced Hepatic Lipogenesis and Inflammation

Area of Science:

• Marine natural products
• Hepatology
• Molecular biology

Background:

• Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition linked to obesity and metabolic disorders.
• Characterized by excessive lipid deposition in liver cells, NAFLD can progress to severe liver damage.
• Palmitate-induced lipotoxicity serves as a model for studying NAFLD pathogenesis.

Purpose of the Study:

• To investigate the protective effects of diphloreth হাইড্রোক্সিকারমালল (DPHC), a seaweed-derived polyphenol, against palmitate-induced liver lipotoxicity.
• To elucidate the molecular mechanisms underlying DPHC's protective actions.
• To evaluate DPHC's potential as a therapeutic agent for fatty liver diseases.

Main Methods:

• In vitro studies using palmitate-treated liver cells.
• Analysis of lipogenesis-related gene and protein expression (SREBP1, C/EBPα, ChREBP, FAS).
• Assessment of AMP-activated protein kinase (AMPK) and sirtuin 1 (SIRT1) signaling.
• In vivo studies using a zebrafish model of liver lipotoxicity.

Main Results:

• DPHC treatment significantly reduced palmitate-induced cytotoxicity, triglyceride content, and lipid accumulation in liver cells.
• DPHC inhibited the expression of key lipogenic genes and proteins, including SREBP1, C/EBPα, ChREBP, and FAS.
• DPHC reversed the palmitate-induced decrease in phosphorylated AMPK and SIRT1 protein levels.
• In zebrafish, DPHC mitigated liver toxicity and inflammation while enhancing AMPK and SIRT1 signaling.

Conclusions:

• DPHC exhibits significant protective effects against palmitate-induced liver toxicity and lipogenesis.
• The mechanism involves the suppression of lipogenic pathways and the activation of AMPK/SIRT1 signaling.
• DPHC demonstrates potential as a therapeutic or preventive agent for non-alcoholic fatty liver disease.